Compare NAMS & PII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAMS | PII |
|---|---|---|
| Founded | 2019 | 1954 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | N/A | 1994 |
| Metric | NAMS | PII |
|---|---|---|
| Price | $29.64 | $73.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | $46.75 | ★ $62.27 |
| AVG Volume (30 Days) | ★ 961.2K | 760.6K |
| Earning Date | 05-06-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 4.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,152,000,000.00 |
| Revenue This Year | $17.96 | $1.20 |
| Revenue Next Year | $540.65 | $4.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.14 | $47.14 |
| 52 Week High | $42.21 | $75.25 |
| Indicator | NAMS | PII |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 59.45 |
| Support Level | $29.23 | $61.47 |
| Resistance Level | $37.29 | $74.15 |
| Average True Range (ATR) | 1.88 | 2.53 |
| MACD | -0.42 | 0.52 |
| Stochastic Oscillator | 8.00 | 84.67 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.